![]() |
Name |
5-[5-[(1R)-1-hydroxyethyl]-2,5-dihydrofuran-2-yl]oxolan-2-one
|
Molecular Formula | C10H14O4 | |
IUPAC Name* |
5-[5-[(1R)-1-hydroxyethyl]-2,5-dihydrofuran-2-yl]oxolan-2-one
|
|
SMILES |
C[C@H](C1C=CC(O1)C2CCC(=O)O2)O
|
|
InChI |
InChI=1S/C10H14O4/c1-6(11)7-2-3-8(13-7)9-4-5-10(12)14-9/h2-3,6-9,11H,4-5H2,1H3/t6-,7?,8?,9?/m1/s1
|
|
InChIKey |
SJSGYYGIRSKXTM-LJSVPSOQSA-N
|
|
Synonyms |
DIPLOBIFURANYLONE B
|
|
CAS | NA | |
PubChem CID | 133673115 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 198.22 | ALogp: | 0.1 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 14 | QED Weighted: | 0.526 |
Caco-2 Permeability: | -4.704 | MDCK Permeability: | 0.00024131 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.006 |
Human Intestinal Absorption (HIA): | 0.199 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.825 |
Blood-Brain-Barrier Penetration (BBB): | 0.747 | Plasma Protein Binding (PPB): | 19.79% |
Volume Distribution (VD): | 1.651 | Fu: | 61.08% |
CYP1A2-inhibitor: | 0.052 | CYP1A2-substrate: | 0.103 |
CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.478 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.474 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.293 |
CYP3A4-inhibitor: | 0.038 | CYP3A4-substrate: | 0.258 |
Clearance (CL): | 4.141 | Half-life (T1/2): | 0.861 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.044 |
Drug-inuced Liver Injury (DILI): | 0.392 | AMES Toxicity: | 0.27 |
Rat Oral Acute Toxicity: | 0.135 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.098 | Carcinogencity: | 0.206 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.055 |
Respiratory Toxicity: | 0.04 |